Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2026
>
Clinical Cancer Trials Help Boost Long-Term Cancer Survivorship Statistics
Clinical Cancer Trials Help Boost Long-Term Cancer Survivorship Statistics
Read also
Advanced Breast Cancer Clinical Trials: Gedatolisib Nearly Doubles PFS
Dr. Hurvitz presents Phase 3 VIKTORIA-1 trial data showing gedatolisib nearly doubles progression-free survival in PIK3CA+ advanced breast cancer.
AI Drug Discovery and Development Boosts Phase 3 Success, Says AZ CEO
AstraZeneca CEO Pascal Soriot highlights how artificial intelligence tools optimize molecule design and predict clinical success in late-stage trials.
How Nonprofits Rescue Shelved Rare Disease Drug Pipelines From Pharma
Children’s Tumor Foundation CEO Annette Bakker discusses how the nonprofit rescues shelved rare disease drugs to accelerate clinical trial validation.
Survodutide Fatty Liver Disease Treatment Normalizes Liver Fat in Phase 3
Boehringer Ingelheim presented Phase 3 trial data showing survodutide normalized liver fat in 61% of patients with fatty liver disease (MASLD).
